Thermo Fisher Scientific Takes Over PeproTech

On December 30th of last year, Thermo Fisher finalised the acquisition of PeproTech for approximately $1.85 billion.

PeproTech is a bioscience reagents provider that specialises in cell and gene treatments. Thermo Fisher’s own cell culture media collection will go nicely will PeproTech’s existing range.

CEO of Thermo Fisher, Marc Casper, expressed how the takeover will “allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering. This transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. We will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”

Founder of PeproTech, Bob Goldman, commented that he is “pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science.”